Beam Therapeutics (BEAM)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 9, 2021, Beam Therapeutics Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2021.
Proposal 1 — The following nominees were elected as Class I directors to serve on the Company’s board of directors until the Company’s 2024 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes:
NomineeForAgainstAbstentionsBroker Non-Votes
Kristina Burow31,570,3986,874,5498,8837,170,395
Graham Cooper34,139,2494,304,02310,5587,170,395

Proposal 2 — The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2021 was ratified, based on the following votes:
ForAgainstAbstentionsBroker Non-Votes